Pfizer
NYSE:PFEPharmaNew York, United States · Est. 1849 · 88,000 employees
Global pharmaceutical and biotechnology corporation.
84
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
111
Indications↗
Distinct diseases across all programs
3,720
Clinical Trials↗
All sponsored trials (all statuses)
91
Orange Book Patents
Across 17 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
84 drugs in development
Approved5
Phase 330
Phase 227
Phase 127
Preclinical20
By Therapeutic Area
top 6
Oncology
3329%
Infectious Disease
1816%
Immunology
1412%
Hematology
87%
Respiratory
76%
Cardiovascular
54%
R&D Momentum
99/100
Pipeline Velocity
87/100
Trial Completion Rate
82/100
Pipeline Concentration
15/100
Pipeline Freshness
72/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 11, 2026
Completed
DRUG USE INVESTIGATION OF BOSUTINIB FOR CML (POST MARKETING COMMITMENT PLAN)
Jul 11, 2026
Active, not recruiting
A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene
Jul 11, 2026
Completed
A RETROSPECTIVE STUDY TO EVALUATE THE REAL-WORLD EFFECTIVENESS OF LORLATINIB AMONG ROS1-POSITIVE NSCLC PATIENTS
Jul 11, 2026
Completed
Real-World Utilization of Palbociclib as 1L Treatment in Canadian HR+/HER2-women Breast Cancer Patients
Jul 11, 2026
Completed
Secondary Databased Post-marketing Surveillance Study of BNT162b2
Jul 11, 2026
Completed
Ibrance® Post-Marketing Database Study Incidence of Interstitial Lung Disease in Inoperable or Recurrent Breast Cancer Patients Treated With Palbociclib in a Post-marketing Setting: Cohort Study Using the Medical Data Vision (MDV) Database
Jul 10, 2026
Recruiting
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS
Jul 10, 2026
Recruiting
A Multi-Center, Prospective, Non-Interventional Study of Real-World Effectiveness of Etrasimod in Patients With Ulcerative Colitis (ENDEAVOUR-UC)
Jul 10, 2026
Recruiting
A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT PARTICIPANTS TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-07799544 USING A 14C-MICROTRACER APPROACH
Jul 10, 2026
Active, not recruiting
An Open-Label Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Jul 10, 2026
Recruiting
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
Details
Company Info
Company Overview
$160.0B
Mkt Cap
$59.6B
Revenue
$1.0B
Cash
CEOAlbert Bourla
Founded1849
Employees88,000
HQNew York, United States
ExchangeNYSE:PFE
Websitepfizer.com
LinkedInCompany Page
Therapeutic Focus
OncologyNeurologyImmunologyHematologyPsychiatryOtherMetabolic & EndocrineMusculoskeletalRespiratoryGastroenterologyOphthalmologyInfectious DiseaseCardiovascularDermatologyNephrologyRare Disease
Recent SEC Filings
EX-99Feb 3, 2026
PFIZER INC (PFE) (CIK 0000078003)
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(5 drugs)
1
—
4
—
—
Cardiovascular(5 drugs)
Dermatology(4 drugs)
—
—
4
1
1
Dermatology(4 drugs)
Gastroenterology(2 drugs)
—
—
2
—
1
Gastroenterology(2 drugs)
Hematology(8 drugs)
2
2
3
3
—
Hematology(8 drugs)
Immunology(14 drugs)
3
4
5
4
1
Immunology(14 drugs)
Infectious Disease(18 drugs)
2
6
6
6
2
Infectious Disease(18 drugs)
Metabolic & Endocrine(3 drugs)
1
—
1
1
1
Metabolic & Endocrine(3 drugs)
Musculoskeletal(1 drug)
1
—
—
—
—
Musculoskeletal(1 drug)
Nephrology(1 drug)
—
—
—
—
1
Nephrology(1 drug)
Neurology(3 drugs)
1
—
1
1
—
Neurology(3 drugs)
Oncology(33 drugs)
5
12
12
12
1
Oncology(33 drugs)
Psychiatry(1 drug)
—
1
—
—
—
Psychiatry(1 drug)
Rare Disease(2 drugs)
—
—
—
2
—
Rare Disease(2 drugs)
Respiratory(7 drugs)
—
—
4
2
2
Respiratory(7 drugs)
Unknown / Other(12 drugs)
5
3
3
3
—
Unknown / Other(12 drugs)
Regulatory
Regulatory Timeline
20151 event
FDADec 28
Zometa — ZOLEDRONIC ACID
Application NDA204016 (NDA)
20172 events
FDAAug 4
Aldactone — CAROSPIR
Application NDA209478 (NDA)
FDAApr 20
Acanya — CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
Application NDA208083 (NDA)
20185 events
FDANov 21
Daurismo — DAURISMO
Application NDA210656 (NDA)
FDANov 2
Lorbrena — LORBRENA
Application NDA210868 (NDA)
FDASep 27
Vizimpro — VIZIMPRO
Application NDA211288 (NDA)
FDAJun 27
Braftovi — BRAFTOVI
Application NDA210496 (NDA)
FDAJun 27
Mektovi — MEKTOVI
Application NDA210498 (NDA)
20192 events
FDADec 18
Padcev — PADCEV EJFV
Application BLA761137 (BLA)
FDANov 1
Ibrance — IBRANCE
Application NDA212436 (NDA)
20202 events
FDAApr 17
Tukysa — TUKYSA
Application NDA213411 (NDA)
FDAFeb 27
Nurtec — NURTEC ODT
Application NDA212728 (NDA)
20212 events
FDADec 7
Acanya — XACIATO
Application NDA215650 (NDA)
FDASep 20
TIVDAK — TIVDAK
Application BLA761208 (BLA)
20221 event
FDAJan 14
Cibinqo — CIBINQO
Application NDA213871 (NDA)
20234 events
FDAOct 20
Coxanto — COXANTO
Application NDA217927 (NDA)
FDAJun 23
Opzelura — LITFULO
Application NDA215830 (NDA)
FDAJun 20
Talzenna — TALZENNA
Application NDA211651 (NDA)
FDAMar 9
Zavzpret — ZAVZPRET
Application NDA216386 (NDA)
20241 event
FDAMar 7
Talzenna — TALZENNA
Application NDA217439 (NDA)
20261 event
SECFeb 3
PFIZER INC (PFE) (CIK 0000078003)
Accession: 001-03619
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)